1. MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy
   Chameli Ratan et al, 2021, Current Cancer Drug Targets CrossRef
2. Immunotherapy for HPV negative head and neck squamous cell carcinoma
   Binyumeng Jiang et al, 2024, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
3. Breast Cancer Vaccine Containing a Novel Toll-like Receptor 7 Agonist and an Aluminum Adjuvant Exerts Antitumor Effects
   Shuquan Zhang et al, 2022, International Journal of Molecular Sciences CrossRef
4. Advances in Tumor Antigen‐Based Anticancer Immunotherapy: Recent Progress, Prevailing Challenges, and Future Perspective
   Wei Shi et al, 2023, Advanced Therapeutics CrossRef
5. Combination Therapy with a TLR7 Agonist and a BRD4 Inhibitor Suppresses Tumor Growth via Enhanced Immunomodulation
   Yong-Si Liu et al, 2024, International Journal of Molecular Sciences CrossRef
6. An efficient and safe MUC1-dendritic cell-derived exosome conjugate vaccine elicits potent cellular and humoral immunity and tumor inhibition in vivo
   Haomiao Zhu et al, 2022, Acta Biomaterialia CrossRef
7. Comparison of mucin-1 in human breast cancer and canine mammary gland tumor: a review study
   Rana Vafaei et al, 2022, Cancer Cell International CrossRef
8. MUC1 and MUC16: critical for immune modulation in cancer therapeutics
   Xinyi Chen et al, 2024, Frontiers in Immunology CrossRef
9. Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape
   Manju Lekshmy et al, 2023, Pharmaceuticals CrossRef
10. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
    Feng Ye et al, 2023, Molecular Cancer CrossRef
11. Glycolipid‐peptide conjugate vaccines elicit CD8+ T‐cell responses and prevent breast cancer metastasis
    Olivia K Burn et al, 2022, Clinical & Translational Immunology CrossRef
12. Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy
    Dhruv Varshney et al, 2021, The AAPS Journal CrossRef
13. Advances in MUC1-Mediated Breast Cancer Immunotherapy
    Zhifeng Li et al, 2022, Biomolecules CrossRef
14. Toll‐like receptors in health and disease
    Kunyu Wang et al, 2024, MedComm CrossRef
15. Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine
    Shi-Hao Zhou et al, 2022, Frontiers in Immunology CrossRef
16. Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern
    Ru-Yan Zhang et al, 2022, ACS Infectious Diseases CrossRef